GLOW Blend: GHK-Cu | BPC-157 | TB-500 Vial

Glow Blend is a three-component peptide combination of GHK-Cu (the copper-binding tripeptide glycyl-L-histidyl-L-lysine, complexed with copper), BPC-157 (the synthetic stable gastric pentadecapeptide derived from human Body Protection Compound), and TB-500 (the N-acetylated 17–23 fragment of thymosin beta-4). The three components are paired in a single product because their mechanisms are commonly framed as complementary in research and clinical-anecdote contexts: GHK-Cu modulates collagen and elastin synthesis, antioxidant gene expression, and dermal extracellular matrix remodeling; BPC-157 modulates nitric oxide signaling and growth factor expression to support gastrointestinal, vascular, and connective-tissue healing; and TB-500 sequesters G-actin to drive cell migration, angiogenesis, and post-injury tissue remodeling. All three individual compounds are also available as standalone products in our catalog, where their evidence bases are summarized in greater depth.

The peer-reviewed evidence summarized below is drawn from studies of each compound separately. No published peer-reviewed work has tested the specific GHK-Cu + BPC-157 + TB-500 combination at the amounts or ratios sold in this product.

Important Note on the Evidence Base

To our knowledge, no peer-reviewed clinical or preclinical study has tested the specific GHK-Cu + BPC-157 + TB-500 three-component combination at the amounts or ratios sold in this product. The rationale for combining them is mechanistic complementarity (different signaling pathways, all three implicated in tissue repair and dermal remodeling) and clinical anecdote in the peptide-therapy community — not formal head-to-head, combination-vs-monotherapy, or concentration-response data on the blend itself. Each individual component has its own evidence-base limitations, summarized briefly in the citations below and in greater depth on the respective standalone product descriptions:

• GHK-Cu — substantial human dermal-application literature, much of it cosmetic-industry-affiliated. Mechanistic gene expression studies are well replicated.
• BPC-157 — evidence base is concentrated in a single research group (Sikiric and collaborators at the University of Zagreb), with limited fully independent replication. Most studies are rodent models.
• TB-500 — commercial “TB-500” is the N-acetylated 17–23 fragment of thymosin beta-4, NOT the full-length 43-amino-acid Tβ4 protein. Peer-reviewed clinical trials in the Tβ4 family (RGN-259 ophthalmic, RGN-352 cardiac) used full-length Tβ4. Whether the heptapeptide fragment fully recapitulates the parent protein’s effects in vivo is unresolved. TB-500 is on the World Anti-Doping Agency prohibited list.

This product is for laboratory research only. None of the three components is approved by the FDA or EMA.

Published Research on the Component Compounds

About the Compounds

GHK-Cu

• Compound class: copper-bound tripeptide; endogenous human peptide
• Sequence: glycyl-L-histidyl-L-lysine bound to a Cu²⁺ ion (Gly-His-Lys:Cu)
• CAS Number: 89030-95-5 (GHK-Cu complex); 49557-75-7 (free GHK tripeptide)
• Molecular Formula (peptide): C₁₄H₂₄N₆O₄ (free tripeptide); the complex carries a single Cu²⁺
• Molecular Weight: 340.38 g/mol (free tripeptide); 403.93 g/mol (Cu complex)
• Mechanism: copper-dependent regulation of collagen, elastin, and antioxidant gene expression in dermal and connective tissue
• Regulatory status: not approved by the FDA or EMA. Endogenous human peptide

BPC-157

• Compound class: synthetic stable gastric pentadecapeptide; partial sequence of human Body Protection Compound
• Sequence: H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH (GEPPPGKPADDAGLV)
• CAS Number: 137525-51-0
• Molecular Formula: C₆₂H₉₈N₁₆O₂₂
• Molecular Weight: 1419.55 g/mol
• Mechanism (working): modulation of nitric oxide system, VEGFR-2 expression, and growth factor signaling supporting GI, vascular, and connective-tissue repair
• Regulatory status: not approved by the FDA or EMA

TB-500

• Compound class: synthetic N-acetylated heptapeptide; thymosin beta-4 (17–23) fragment
• Sequence: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ)
• CAS Number: 885340-08-9
• Molecular Formula: C₃₈H₆₈N₁₀O₁₄
• Molecular Weight: 889.02 g/mol
• Mechanism: actin-sequestering motif of Tβ4; modulates cell migration, angiogenesis, and tissue repair signaling
• Regulatory status: not approved by the FDA or EMA. Prohibited by the World Anti-Doping Agency in competition

Product Specifications

• Format: lyophilized peptide blend in vial (three-component blend; reconstitute with bacteriostatic water; refer to COA for component ratio)
• Strength: 70 mg total peptide content per vial
• Purity: ≥99% (HPLC verified, each component)
• Container: sealed glass vial (lyophilized powder)
• Certificate of Analysis: lot-specific COA available, with separate purity and identity verification for all three component peptides

See the FDA Disclosure, Storage Instructions, and RUO tabs for handling, storage, and regulatory information.

References

1. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. doi:10.1155/2015/648108
2. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. doi:10.1016/S0736-0266(03)00110-4
3. Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. doi:10.1038/nature03000
4. Sosne G, Kleinman HK, Springs C, Gross RH, Sung J, Kang S. 0.1% RGN-259 (Thymosin β4) ophthalmic solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked Phase III clinical trial. Int J Mol Sci. 2022;24(1):554. doi:10.3390/ijms24010554